fitc conjugated anti-human fcγriia antibody, clone iv.3  (STEMCELL Technologies Inc)

Journal: Frontiers in Immunology

Article Title: Sub-neutralizing levels of antibodies against RSV F protein enhance RSV infection via Fc-FcγR interactions

doi: 10.3389/fimmu.2025.1594937

Figure Lengend Snippet: ADE requires the co-engagement of FcγRI and TLR4. (A) The percentage of RFP+ THP-1 cells at 12 h post-infection was detected by flow cytometry after blocking FcγRI, FcγRIIa and TLR4. (B) The expression of FcγRI, FcγRIIa and FcγRIIb in THP-1 cells at 24 h post-infection using qPCR. ** for p ≤ 0.01; ^^^ for p ≤ 0.001; ****, ^^^^ for p ≤ 0.0001. ns means no statistical significance compared to the T0 group.

Article Snippet: THP-1 cells were pre-incubated for 1 h with 20 μg/mL neutralization antibodies against TLR4 (clone HTA125) (Invitrogen,14-9917-82), or blocking antibodies (10 μg/mL) against FcγRI (10.1, BD), or FcγRIIa (BioXcell, BE0224-1MG).

Techniques: Infection, Flow Cytometry, Blocking Assay, Expressing

Journal: Rheumatology (Oxford, England)

Article Title: Immune complex-mediated neutrophil activation in patients with polymyalgia rheumatica

doi: 10.1093/rheumatology/keac722

Figure Lengend Snippet: FcγRIIA-mediated neutrophil activation induced by plasma from patients with PMR. Plasma from HCs ( n = 8) and patients with PMR ( n = 8) were incubated in vitro with neutrophils isolated from a healthy object in the presence or absence of the FcγRIIA-blocking antibody (Clone IV.3) for 120 min and assessed for its capacity to up-regulate the neutrophil activation surface makers CD66b ( A ) and CD11b ( B ). Results are shown as the mean fluorescence intensity (MFI). Statistical analyses were done using the Mann–Whitney U -test as well as the Wilcoxon signed-rank test; ** P < 0.01, *** P < 0.001. HC: healthy control; ns: not significant

Article Snippet: To assess neutrophil activation, neutrophils at a concentration of 3 × 10 5 cells/well were incubated in the presence or absence of the human FcγRIIA blocking antibody (IV.3) (5 μg/ml; Caprico Biotechnologies, Norcross, GA, USA) for 30 min before addition of stimuli, such as R848 (3.5 μg/ml), or plasma samples from patients with PMR ( n = 8) and HCs ( n = 8) (1:50 dilution) for an additional 120 min.

Techniques: Activation Assay, Clinical Proteomics, Incubation, In Vitro, Isolation, Blocking Assay, Fluorescence, MANN-WHITNEY, Control

Journal: Cell reports

Article Title: Maternal Anti-Dengue IgG Fucosylation Predicts Susceptibility to Dengue Disease in Infants

doi: 10.1016/j.celrep.2020.107642

Figure Lengend Snippet:

Article Snippet: To assess FcγR expression cells were stained at 1:100 with a FITC conjugated anti-human FcγRIIa antibody, clone IV.3 (STEMCELL Technologies; 60012FI); Brilliant Violet 711 conjugated anti-human FcγRIII, clone 3G8 (Biolegend; 302044); an FcγRIIb antibody clone 2B6 (gifted by the Ravetch lab, Rockefeller University) conjugated to Alexa Fluor 647 (ThermoFisher; A20186) and an APC conjugated anti-human FcγRI, clone 10.1 (Biolegend, 305014) for 30 minutes at 4°C.

Techniques: Virus, Recombinant, Plasmid Preparation, Software